Wang Shang-Yu, Hu Hong-Zhi, Qing Xiang-Cheng, Zhang Zhi-Cai, Shao Zeng-Wu
Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
J Cancer. 2020 Jan 1;11(1):69-82. doi: 10.7150/jca.36588. eCollection 2020.
Osteosarcoma is the most common primary malignant bone tumor mainly occurred in children and adolescence, and chemotherapy is limited for the side effects and development of drug resistance. Advances in nanotechnology and knowledge of cancer biology have led to significant improvements in developing tumor-targeted drug delivery nanocarriers, and some have even entered clinically application. Delivery of chemotherapeutic agents by functionalized smart nanocarriers could protect the drugs from rapid clearance, prolong the circulating time, and increase the drug concentration at tumor sites, thus enhancing the therapeutic efficacy and reducing side effects. Various drug delivery nanocarriers have been designed and tested for osteosarcoma treatment, but most of them are still at experimental stage, and more further studies are needed before clinical application. In this present review, we briefly describe the types of commonly used nanocarriers in osteosarcoma treatment, and discuss the strategies for osteosarcoma-targeted delivery and controlled release of drugs. The application of nanoparticles in the management of metastatic osteosarcoma is also briefly discussed. The purpose of this article is to present an overview of recent progress of nanoscale drug delivery platforms in osteosarcoma, and inspire new ideas to develop more effective therapeutic options.
骨肉瘤是最常见的原发性恶性骨肿瘤,主要发生于儿童和青少年,化疗因副作用和耐药性的产生而受到限制。纳米技术的进步和癌症生物学知识推动了肿瘤靶向药物递送纳米载体研发的显著进展,其中一些甚至已进入临床应用阶段。通过功能化智能纳米载体递送化疗药物可以保护药物不被快速清除,延长其循环时间,并提高肿瘤部位的药物浓度,从而增强治疗效果并减少副作用。人们已经设计并测试了各种用于治疗骨肉瘤的药物递送纳米载体,但其中大多数仍处于实验阶段,在临床应用之前还需要更多深入研究。在本综述中,我们简要描述了骨肉瘤治疗中常用纳米载体的类型,并讨论了骨肉瘤靶向给药和药物控释的策略。还简要讨论了纳米颗粒在转移性骨肉瘤治疗中的应用。本文旨在概述纳米级药物递送平台在骨肉瘤治疗方面的最新进展,并激发新思路以开发更有效的治疗方案。